Financial reports
20-F
2022 FY
Annual report (foreign)
23 Mar 23
20-F
2021 FY
Annual report (foreign)
24 Mar 22
20-F
2020 FY
Annual report (foreign)
24 Mar 21
20-F
2019 FY
Annual report (foreign)
25 Mar 20
20-F
2018 FY
Annual report (foreign)
5 Apr 19
20-F
2017 FY
Annual report (foreign)
6 Apr 18
20-F
2016 FY
Annual report (foreign)
4 Apr 17
20-F
2015 FY
Annual report (foreign)
8 Apr 16
Current reports
6-K
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
17 Jan 24
6-K
Publication of a transparency notification received from Fortress Investment Group LLC
21 Dec 23
6-K
Current report (foreign)
18 Dec 23
6-K
Celyad announces management change
4 Dec 23
6-K
Current report (foreign)
4 Dec 23
6-K
Celyad Oncology reports third quarter 2023 financial
24 Nov 23
6-K
Publication of a transparency notification received from
21 Nov 23
6-K
Current report (foreign)
21 Nov 23
6-K
Information on the Total Number of Voting Rights and Total Number of shares with single voting rights
15 Nov 23
6-K
Current report (foreign)
27 Oct 23
Registration and prospectus
15F-12B
Securities registration termination (foreign)
9 Feb 24
25-NSE
Exchange delisting
10 Jul 23
424B5
Prospectus supplement for primary offering
7 Jan 21
424B5
Prospectus supplement for primary offering
11 Sep 20
F-3
Shelf registration (foreign)
28 Aug 20
424B3
Prospectus supplement
22 Jun 20
424B5
Prospectus supplement for primary offering
12 Sep 19
424B5
Prospectus supplement for primary offering
10 Sep 19
424B3
Prospectus supplement
15 Oct 18
424B5
Prospectus supplement for primary offering
18 May 18
Proxies
No filings
Other
UPLOAD
Letter from SEC
26 Jan 22
CORRESP
Correspondence with SEC
21 Jan 22
UPLOAD
Letter from SEC
15 Dec 21
CORRESP
Correspondence with SEC
3 Jun 21
UPLOAD
Letter from SEC
20 May 21
CORRESP
Correspondence with SEC
5 May 21
UPLOAD
Letter from SEC
27 Apr 21
EFFECT
Notice of effectiveness
8 Sep 20
UPLOAD
Letter from SEC
4 Sep 20
CORRESP
Correspondence with SEC
3 Sep 20